Bronte Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P Small-Cap ETF
IJR
|
+$60.6M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$13.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$61.8M |
| 2 |
Berkshire Hathaway Class B
BRK.B
|
+$51.4M |
| 3 |
Interactive Brokers
IBKR
|
+$40.2M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$9.23M |
| 5 |
Match Group
MTCH
|
+$9.07M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 28% |
| 2 | Communication Services | 14.79% |
| 3 | Healthcare | 10.09% |
| 4 | Consumer Discretionary | 7.36% |
| 5 | Consumer Staples | 6.7% |
Similar funds
Bronte Capital Management's Q4 2024 Portfolio in Review
As of Q4 2024, Bronte Capital Management held 25 positions worth $1.27B, up 3% from $1.23B the previous quarter. Its ten largest holdings account for 82% of the portfolio.
Bronte Capital Management withdrew a net $162M in Q4 2024, closing 1 position and reducing 21 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $9.23M position sold in full.
By sector, the portfolio is most concentrated in Financials at 28% of assets, down from 29% a quarter earlier, followed by Communication Services and Healthcare.
Against the trend, Bronte Capital Management added an estimated $60.6M to iShares Core S&P Small-Cap ETF.
- Bronte Capital Management added most to iShares Core S&P Small-Cap ETF in Q4 2024, an estimated $60.6M increase.
- Bronte Capital Management's biggest Q4 2024 reduction was Alphabet (Google) Class A, cutting an estimated $61.8M.
- Bronte Capital Management fully exited Vertex Pharmaceuticals in Q4 2024, selling an estimated $9.23M.
- Bronte Capital Management's ten largest holdings make up 82% of its $1.27B portfolio in Q4 2024.
- Bronte Capital Management opened 0 new positions and closed 1 in Q4 2024.
- Bronte Capital Management's portfolio value rose 3% quarter-over-quarter to $1.27B.
Based on Bronte Capital Management's 13F filing for Q4 2024, filed 10 Feb 2025.